Amyl Therapeutics: Funding, Investors & Team (Oct 2026)
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
Amyl Therapeutics has raised $16.1M across 2 funding rounds on record, the most recent a Series A of $9.6M announced in Sep 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Amyl Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2026.
Amyl Therapeutics Funding Rounds
Amyl Therapeutics raised $6.5M in an undisclosed round announced in Nov 2023.
2.8 years later, a Series A of $9.6M was announced in Sep 2026.
Amyl Therapeutics Investors
9 investors are recorded in total; the 5 named above are those the record identifies.
Amyl Therapeutics Founders and Leadership Team
Contact details for the Amyl Therapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Amyl Therapeutics Funding Compared to Other Biotechnology Startups
Amyl Therapeutics' latest round of $9.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amyl Therapeutics in Biotechnology and Liège
Companies Similar to Amyl Therapeutics
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
A biopharmaceutical business called Novadip Biosciences was established with the goal of creating,…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
Amyl Therapeutics Funding FAQs
What does Amyl Therapeutics do?
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
How much funding has Amyl Therapeutics raised?
Amyl Therapeutics has raised $16.1M across 2 rounds on record. The most recent is a Series A of $9.6M announced in Sep 2026.
When did Amyl Therapeutics last raise funding?
Amyl Therapeutics' most recent funding round on record is a Series A of $9.6M, announced in Sep 2026.
Who has invested in Amyl Therapeutics?
Investors on record for Amyl Therapeutics include Mérieux Equity Partners, Sambrinvest, Smedvig, Meusinvest (Noshaq), Evren Ucok. FundedIQ records 9 investors in total.
Who is the CEO of Amyl Therapeutics?
Pierre Vandepapeliere is listed as CEO at Amyl Therapeutics.
Where is Amyl Therapeutics headquartered?
Amyl Therapeutics is based in Liège, Liege, Belgium.
How many employees does Amyl Therapeutics have?
Amyl Therapeutics is in the 1-10 employee band.
When was Amyl Therapeutics founded?
Amyl Therapeutics was founded in 2020.
How does Amyl Therapeutics' funding compare to other Biotechnology startups?
Amyl Therapeutics' latest round of $9.6M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Amyl Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amyl Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.